

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1459 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/073,985	02/14/2002	Tadakiyo Nakagawa	219620US0CONT	6107
22850 75	90 07/28/2003			
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER	
			TRUONG, TAMTHOM NGO	
ALLAANDRIA	ALLANDINA, VA 22517			
			ART UNIT	PAPER NUMBER
			1624	
•			DATE MAILED: 07/28/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/073,985	NAKAGAWA ET AL.
Office Action Summary	Examin r	Art Unit
	Tamthom N. Truong	1624
Th MAILING DATE of this communication app Period for Reply	pears on the c ver sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply within the statutory minimum of thirty (3 will apply and will expire SIX (6) MONTH, acuse the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on	·	
2a) ☐ This action is FINAL . 2b) ☑ Th	is action is non-final.	
Since this application is in condition for alloward closed in accordance with the practice under a Disposition of Claims		
4) Claim(s) 1 and 28-45 is/are pending in the app	olication.	
4a) Of the above claim(s) is/are withdraw	wn from consideration.	
5) Claim(s) 41 and 42 is/are allowed.		
6) Claim(s) <u>1,28,32,35 and 43-45</u> is/are rejected.		
7) Claim(s) 29-31,33,34 and 36-40 is/are objected	d to.	
8) Claim(s) are subject to restriction and/or	r election requirement.	
Application Papers		
9) The specification is objected to by the Examine	r.	
10)☐ The drawing(s) filed on is/are: a)☐ accept	oted or b) objected to by the	Examiner.
Applicant may not request that any objection to the	• • • • • • • • • • • • • • • • • • • •	` '
11) The proposed drawing correction filed on		approved by the Examiner.
If approved, corrected drawings are required in rep	•	
12) The oath or declaration is objected to by the Example 12.	aminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a)⊠ All b)□ Some * c)□ None of:		
 Certified copies of the priority documents 	s have been received.	
2. Certified copies of the priority documents	s have been received in App	lication No. <u>09/731,729</u> .
Copies of the certified copies of the prior application from the International But See the attached detailed Office action for a list of the certified services.	reau (PCT Rule 17.2(a)).	-
14) Acknowledgment is made of a claim for domestic	•	
a) ☐ The translation of the foreign language pro 15) ☐ Acknowledgment is made of a claim for domesti	visional application has been	n received.
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6	5) Notice of Info	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)

Application/Control Number: 10/073,985

Art Unit: 1624

DETAILED ACTION

This application is a CON of 09/731,729, now US 6,410,538.

Both preliminary amendments have been entered. Thus, claims 2-27 are now cancelled, leaving claim 1 for consideration along with new claims 28-45. Note, there are two of "claim 35". So, the second claim 35 through claim 44 have been renumbered as claims 36 - 45 according to Rule 1.126.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 1. Claims 32, 43-45 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:
 - a. Claim 32 lacks antecedent basis for reciting variable "Z", which is not recited in claim 28. Perhaps " Z_1 " was meant. Correction is solicited.
 - b. Claim 43 appears as a duplicate of claim 42.
 - c. Claims 44 and 45 lack antecedent basis because they recite formula (1-3) which is not recited in claim 43. According to the specification, the formula in claim 43 is formula (1-2).

Art Unit: 1624

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

2. Claim 1 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of prior U.S. Patent No. 6,410,538. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 28, and 35 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 24 and 25 of U.S. Patent No. 6,410,538.

Application/Control Number: 10/073,985 Page 4

Art Unit: 1624

Although the conflicting claims are not identical, they are not patentably distinct from each other for the following reasons:

- a. Claim 24 of US'538 recites "an anticoagulant compositioncomprises one or more...compounds...according to claim 1", and the instant claim 28 recites "a composition" comprises one or more benzamidine compounds that have the same scope of claim 1 in US'538.
- b. Likewise, claim 25 of US'538 recites "an anticoagulant composition...comprises one or more...compounds ...according to claim 8", and the instant claim 35 recites "a composition" comprises one or more benzamidine compounds that have the same scope of claim 8 in US'538.
- c. Although both claims 24 and 25 recite the intended use of "anticoagulant", said preamble does not have patentable weight since it does not contribute to the structural changes in the composition. Another words, pharmaceutical compositions are standard. Thus, it would have been obvious for one skilled in the art to make the claimed compositions in view of those in US'538.
- 4. Claims 1 and 28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4, and 10 of copending Application No. 10/164,623 (US 2002/0193348). Although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds and

Application/Control Number: 10/073,985

Art Unit: 1624

composition recited in the copending application are totally embraced by those recited in the

instant claims 1 and 28, particularly when Z represents –(CH₂)_m-P(=O)-OR⁴-(OR⁵).

This is a provisional obviousness-type double patenting rejection because the conflicting

Page 5

claims have not in fact been patented.

Claim Objections

5. Claims 29-31, 33, 34, and 36-40 are objected to as being dependent upon a rejected base

claim, but would be allowable if rewritten in independent form including all of the limitations of

the base claim and any intervening claims. The reference of Takayanagi et. al. (WO 98/31661)

teaches related compounds; however, said reference does not teach a substituent equivalent to the

instant Z_1 .

Allowable Subject Matter

6. Claims 41 and 42 are allowable since the prior arts of record do not teach the composition

of the particular formula (1-2). Note, claims 41 and 42 do not have the same scope as claim 28;

therefore, the double patenting rejection is not applicable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (9:30-5:00) & every Saturday morning (starting

from 4-7-03).

Art Unit: 1624

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Tamthom N. Truong

Patent Examiner
Art Unit 1624

July 28, 2003